#1 - Eli Lilly and Company
NYSE:LLY - See Stock Forecast- Stock Price:
- $951.97 (+$2.00)
- Market Cap:
- $904.76 billion
- P/E Ratio:
- 140.2
- Dividend Yield:
- 0.56%
- Consensus Rating:
- Moderate Buy (0 Strong Buy Ratings, 16 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $956.88 (0.5% Upside)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Eli Lilly and Company Stock
Pros
-
Eli Lilly and Company has a strong dividend history, currently offering a $1.30 dividend per share, representing a 0.59% yield. This consistent dividend payout can provide investors with a steady income stream.
-
Insider activity shows major shareholders selling shares at high prices, indicating confidence in the company's future growth prospects. This can be seen as a positive signal for potential investors.
-
Institutional investors have been increasing their stakes in Eli Lilly and Company, suggesting a favorable outlook on the company's performance and potential for growth.
Cons
-
The company's payout ratio of 76.58% indicates that a significant portion of its earnings is being distributed as dividends, potentially limiting reinvestment for future growth initiatives.
-
Recent insider selling activity, including by major shareholders and executives, could raise concerns about the company's internal outlook or potential challenges ahead.
-
Eli Lilly and Company's beta of 0.41 suggests that the stock may be less volatile compared to the market, which could limit potential returns for investors seeking higher-risk opportunities.
#2 - Novo Nordisk A/S
NYSE:NVO - See Stock Forecast- Stock Price:
- $134.96 (-$0.85)
- Market Cap:
- $609.45 billion
- P/E Ratio:
- 46.5
- Dividend Yield:
- 0.55%
- Consensus Rating:
- Moderate Buy (0 Strong Buy Ratings, 6 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $145.17 (7.6% Upside)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Novo Nordisk A/S Stock
Pros
-
Novo Nordisk is a pharmaceutical company with a strong focus on research and development, particularly in the field of diabetes.
-
The company has a diverse geographic presence, operating in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
-
Novo Nordisk has a solid track record of manufacturing and distributing pharmaceutical products.
Cons
-
Novo Nordisk faces competition in the pharmaceutical industry, which could impact its market share and profitability.
-
The company's focus on diabetes products may limit its diversification and expose it to risks associated with changes in the healthcare landscape.
-
Recent developments in the natural resource exploration sector of Novo Resources Corp., a subsidiary of Novo Nordisk, may not align with investor expectations in the pharmaceutical industry.
#3 - UnitedHealth Group
NYSE:UNH - See Stock Forecast- Stock Price:
- $578.09 (-$2.56)
- Market Cap:
- $533.82 billion
- P/E Ratio:
- 35.3
- Dividend Yield:
- 1.45%
- Consensus Rating:
- Buy (1 Strong Buy Ratings, 18 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $614.17 (6.2% Upside)
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of UnitedHealth Group Stock
Pros
-
UnitedHealth Group's stock price has been steadily increasing, reaching $574.24 on the latest trading day, indicating positive momentum.
-
The company has a strong financial position with a current ratio of 0.88 and a quick ratio of 0.85, reflecting good liquidity levels.
-
UnitedHealth Group has consistently increased its dividend payout, providing investors with a stable source of income.
Cons
-
The company's stock has a relatively high P/E ratio of 34.97, which may indicate that the stock is currently overvalued.
-
UnitedHealth Group's debt-to-equity ratio of 0.67 suggests a moderate level of financial leverage, which could pose risks in uncertain economic conditions.
-
Insider selling activity, such as the recent sale of shares by the chief accounting officer, may raise concerns about insider sentiment towards the company's future prospects.
#4 - Johnson & Johnson
NYSE:JNJ - See Stock Forecast- Stock Price:
- $161.40 (+$1.24)
- Market Cap:
- $388.44 billion
- P/E Ratio:
- 10.1
- Dividend Yield:
- 3.12%
- Consensus Rating:
- Hold (0 Strong Buy Ratings, 6 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $173.21 (7.3% Upside)
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Johnson & Johnson Stock
Pros
-
Johnson & Johnson reported strong quarterly earnings, beating analyst estimates, indicating a financially healthy company.
-
The company has a solid return on equity of 36.60%, showcasing efficient use of shareholder funds to generate profits.
-
Johnson & Johnson has a high net margin of 46.34%, indicating strong profitability in its operations.
Cons
-
Johnson & Johnson's dividend payout ratio is relatively high at 30.92%, which may limit future dividend growth or reinvestment in the business.
-
While the company has shown revenue growth, the rate of growth at 4.3% may not be sufficient for some investors seeking higher growth opportunities.
-
Market volatility and regulatory challenges in the healthcare sector could impact Johnson & Johnson's stock price and performance.
#5 - AbbVie
NYSE:ABBV - See Stock Forecast- Stock Price:
- $196.53 (+$0.38)
- Market Cap:
- $347.05 billion
- P/E Ratio:
- 58.3
- Dividend Yield:
- 3.21%
- Consensus Rating:
- Moderate Buy (0 Strong Buy Ratings, 13 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $190.29 (-3.2% Downside)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of AbbVie Stock
Pros
-
AbbVie's stock price has shown consistent growth, reaching $186.52 per share recently, indicating a positive trend for potential returns.
-
Analysts have given AbbVie a consensus rating of "Moderate Buy" with an average price target of $190.29, suggesting further upside potential.
-
Recent institutional trading activities have seen hedge funds and institutional investors increasing their stakes in AbbVie, indicating confidence in the company's future performance.
Cons
-
There is a risk associated with any pharmaceutical company due to factors like regulatory challenges, patent expirations, and competition, which could impact AbbVie's revenue and profitability.
#6 - Merck & Co., Inc.
NYSE:MRK - See Stock Forecast- Stock Price:
- $116.00 (+$0.86)
- Market Cap:
- $293.81 billion
- P/E Ratio:
- 128.9
- Dividend Yield:
- 2.72%
- Consensus Rating:
- Moderate Buy (3 Strong Buy Ratings, 9 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)
- Consensus Price Target:
- $134.58 (16.0% Upside)
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Merck & Co., Inc. Stock
Pros
-
Merck & Co., Inc. stock has been trading up, showing positive momentum in the market.
-
Analysts have given Merck & Co., Inc. a consensus rating of "Moderate Buy" with a positive average price target.
-
Recent increase in institutional investments in Merck & Co., Inc. indicates confidence from financial experts.
Cons
-
Merck & Co., Inc. has a relatively high PE ratio of 128.00, which may indicate overvaluation.
-
There has been a recent cut in earnings outlook for Merck & Co., Inc., which could impact short-term stock performance.
-
Some analysts have lowered their price targets for Merck & Co., Inc., signaling potential concerns in the market.
#7 - AstraZeneca
NASDAQ:AZN - See Stock Forecast- Stock Price:
- $85.56 (+$0.43)
- Market Cap:
- $263.95 billion
- P/E Ratio:
- 41.9
- Dividend Yield:
- 1.16%
- Consensus Rating:
- Moderate Buy (2 Strong Buy Ratings, 6 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $89.75 (4.9% Upside)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of AstraZeneca Stock
Pros
-
AstraZeneca's stock price has been showing a consistent upward trend, reaching a 12-month high of $80.86.
-
The company reported a strong quarterly revenue of $12.45 billion, surpassing analyst estimates.
-
Analysts predict AstraZeneca will post 4.02 earnings per share for the current fiscal year, indicating potential growth.
Cons
-
AstraZeneca recently cut its dividend, which may impact income-seeking investors who rely on dividends for returns.
-
The company's dividend payout ratio is high at 94.61%, indicating a significant portion of earnings is being distributed as dividends.
-
While revenue was up 9.1% compared to the same quarter last year, it slightly missed analyst estimates, signaling potential challenges in meeting expectations.
#8 - Novartis
NYSE:NVS - See Stock Forecast- Stock Price:
- $117.62 (+$0.49)
- Market Cap:
- $234.45 billion
- P/E Ratio:
- 15.9
- Dividend Yield:
- 2.12%
- Consensus Rating:
- Hold (0 Strong Buy Ratings, 2 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings)
- Consensus Price Target:
- $118.13 (0.4% Upside)
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Novartis Stock
Pros
-
Novartis AG has recently launched a groundbreaking new drug that is expected to significantly boost revenue and profits.
-
The company's stock price has been steadily increasing over the past year, indicating positive investor sentiment.
-
Novartis AG has a strong pipeline of innovative products in development, which could drive future growth.
Cons
-
There is potential regulatory risk associated with the pharmaceutical industry, which could impact Novartis AG's operations and profitability.
-
Competition in the healthcare sector is intense, and Novartis AG may face challenges in maintaining market share and pricing power.
-
Global economic uncertainties and geopolitical tensions could affect Novartis AG's international operations and revenue streams.
#9 - Thermo Fisher Scientific
NYSE:TMO - See Stock Forecast- Stock Price:
- $610.17 (-$4.37)
- Market Cap:
- $233.08 billion
- P/E Ratio:
- 39.1
- Dividend Yield:
- 0.26%
- Consensus Rating:
- Moderate Buy (0 Strong Buy Ratings, 13 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $618.94 (1.4% Upside)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
#10 - Abbott Laboratories
NYSE:ABT - See Stock Forecast- Stock Price:
- $111.38 (+$0.61)
- Market Cap:
- $193.76 billion
- P/E Ratio:
- 34.7
- Dividend Yield:
- 1.98%
- Consensus Rating:
- Moderate Buy (0 Strong Buy Ratings, 7 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $121.00 (8.6% Upside)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Abbott Laboratories Stock
Pros
-
Abbott Laboratories has a strong track record of consistent revenue growth, which indicates stability and potential for future earnings.
-
The company's diverse product portfolio across pharmaceuticals, diagnostics, nutrition, and medical devices provides a balanced revenue stream and reduces risk associated with dependency on a single product line.
-
Recent insider transactions, such as the sale of shares by an executive vice president, can sometimes indicate confidence in the company's future performance.
Cons
-
Abbott Laboratories' stock price has experienced fluctuations recently, which may indicate volatility and uncertainty in the market.
-
The company's P/E ratio of 33.87 and P/E/G ratio of 2.74 suggest that the stock may be currently overvalued compared to its growth prospects.
-
Edward Jones downgraded Abbott Laboratories from a "buy" rating to a "hold" rating, which could signal concerns about the company's future performance.
#11 - Amgen
NASDAQ:AMGN - See Stock Forecast- Stock Price:
- $329.15 (+$0.60)
- Market Cap:
- $176.57 billion
- P/E Ratio:
- 47.0
- Dividend Yield:
- 2.77%
- Consensus Rating:
- Moderate Buy (0 Strong Buy Ratings, 11 Buy Ratings, 11 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $326.89 (-0.7% Downside)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Amgen Stock
Pros
-
Amgen's stock price has shown resilience, trading at $312.50 on August 19, 2024.
-
Amgen has a diverse portfolio of successful products, including Enbrel, Otezla, and Repatha, catering to various medical needs.
-
Recent analyst reports have raised price targets for Amgen, indicating positive sentiment and potential growth.
Cons
-
Amgen's dividend payout ratio is currently high at 128.57%, indicating a significant portion of earnings being distributed as dividends.
-
Amgen's price-to-earnings ratio of 44.64 may suggest the stock is relatively expensive compared to industry peers.
-
Amgen's debt-to-equity ratio of 11.96 is relatively high, which could pose risks in times of economic downturns.
#12 - Intuitive Surgical
NASDAQ:ISRG - See Stock Forecast- Stock Price:
- $487.42 (+$4.21)
- Market Cap:
- $172.89 billion
- P/E Ratio:
- 88.0
- Consensus Rating:
- Moderate Buy (0 Strong Buy Ratings, 15 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $442.30 (-9.3% Downside)
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Intuitive Surgical Stock
Pros
-
Intuitive Surgical has a strong market capitalization of $170+ billion, indicating stability and potential for growth.
-
The company's PE ratio of 86.67 suggests a solid earnings performance relative to its stock price.
-
Intuitive Surgical's consistent revenue growth of 14.5% year-over-year demonstrates a healthy business trajectory.
Cons
-
The stock's PE ratio of 86.67 may indicate an overvalued position compared to industry peers.
-
Intuitive Surgical's price-to-earnings-growth ratio of 4.97 could suggest limited growth potential relative to its current valuation.
-
With a beta of 1.39, the stock is more volatile than the market average, posing higher risk for investors.
#13 - Pfizer
NYSE:PFE - See Stock Forecast- Stock Price:
- $29.02 (+$0.12)
- Market Cap:
- $164.42 billion
- Dividend Yield:
- 5.85%
- Consensus Rating:
- Moderate Buy (1 Strong Buy Ratings, 6 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $34.54 (19.0% Upside)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Pfizer Stock
Pros
-
Pfizer's recent quarterly earnings per share of $0.60 exceeded analysts' estimates by $0.14, indicating strong financial performance.
-
The company's positive return on equity of 8.31% showcases efficient utilization of shareholder funds to generate profits.
-
Pfizer's revenue growth of 2.1% year-over-year demonstrates a stable and growing business operation.
Cons
-
Pfizer's negative net margin of 4.66% suggests challenges in controlling costs and maximizing profitability.
-
The company's dividend payout ratio of -2,800.00% raises concerns about the sustainability of the dividend payments.
-
Fluctuations in the biopharmaceutical industry, regulatory changes, and patent expirations can impact Pfizer's future revenue and earnings.
#14 - Sanofi
NASDAQ:SNY - See Stock Forecast- Stock Price:
- $55.22 (+$0.44)
- Market Cap:
- $139.86 billion
- P/E Ratio:
- 27.7
- Dividend Yield:
- 2.73%
- Consensus Rating:
- Hold (0 Strong Buy Ratings, 2 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $57.50 (4.1% Upside)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Sanofi Stock
Pros
-
Sanofi has a market capitalization of $134.36 billion, indicating a strong financial position and stability in the market.
-
The company's price-to-earnings ratio of 26.66 suggests that investors are willing to pay $26.66 for every $1 of earnings, which could indicate growth potential.
-
Sanofi's recent quarterly earnings report showed a positive surprise, beating the consensus estimate by $0.05 per share, indicating strong performance.
Cons
-
The company's debt-to-equity ratio of 0.17 may indicate a higher level of debt compared to equity, which could pose a risk in times of financial instability.
-
Sanofi's quick ratio of 0.65 and current ratio of 1.00 may suggest potential liquidity challenges in meeting short-term obligations.
-
Short interest in Sanofi has been increasing, which could indicate bearish sentiment among investors and potential downward pressure on the stock price.
#15 - Stryker
NYSE:SYK - See Stock Forecast- Stock Price:
- $345.32 (+$2.39)
- Market Cap:
- $131.55 billion
- P/E Ratio:
- 39.4
- Dividend Yield:
- 0.96%
- Consensus Rating:
- Moderate Buy (0 Strong Buy Ratings, 15 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $373.11 (8.0% Upside)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Stryker Stock
Pros
-
Stryker Co. reported a strong quarterly earnings result, beating analysts' consensus estimates, which indicates the company's financial health and potential for growth.
-
The company has a consistent track record of increasing dividends, providing investors with a steady income stream. The recent quarterly dividend announcement further solidifies this commitment.
-
Insider trading activities show confidence in the company's future, with key executives like the CFO and Director selling shares at a significant profit, suggesting positive outlooks.
Cons
-
The stock price has been fluctuating around the 50-day and 200-day moving averages, indicating potential volatility and uncertainty in the short to medium term.
-
While the company has shown growth in revenue and earnings, the debt-to-equity ratio of 0.51 may raise concerns about the company's leverage and financial stability, which could impact future growth prospects.
-
Despite positive analyst ratings, there is always a level of risk associated with investing in individual stocks, especially in a competitive industry like medical technology where regulatory changes and market dynamics can influence performance.
#16 - Regeneron Pharmaceuticals
NASDAQ:REGN - See Stock Forecast- Stock Price:
- $1,185.34 (-$6.89)
- Market Cap:
- $130.00 billion
- P/E Ratio:
- 35.0
- Consensus Rating:
- Moderate Buy (1 Strong Buy Ratings, 16 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings)
- Consensus Price Target:
- $1,104.65 (-6.8% Downside)
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
#17 - Elevance Health
NYSE:ELV - See Stock Forecast- Stock Price:
- $542.22 (-$0.82)
- Market Cap:
- $126.02 billion
- P/E Ratio:
- 20.5
- Dividend Yield:
- 1.20%
- Consensus Rating:
- Buy (1 Strong Buy Ratings, 13 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $604.29 (11.4% Upside)
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.
#18 - Vertex Pharmaceuticals
NASDAQ:VRTX - See Stock Forecast- Stock Price:
- $486.11 (-$1.26)
- Market Cap:
- $125.46 billion
- P/E Ratio:
- 31.5
- Consensus Rating:
- Moderate Buy (0 Strong Buy Ratings, 16 Buy Ratings, 7 Hold Ratings, 3 Sell Ratings)
- Consensus Price Target:
- $485.91 (0.0% Downside)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Vertex Pharmaceuticals Stock
Pros
-
Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing therapies for treating cystic fibrosis (CF), a chronic genetic disorder affecting the lungs and digestive system.
-
TRIKAFTA/KAFTRIO, one of Vertex's key products, is approved for people with CF with at least one F508del mutation, providing a significant market opportunity.
-
SYMDEKO/SYMKEVI, another product from Vertex, is also approved for people with CF, expanding the company's product portfolio and revenue potential.
Cons
-
While Vertex Pharmaceuticals has a strong focus on CF therapies, the company's success is heavily dependent on the performance and approval of its existing products in the market.
-
Regulatory challenges and competition in the biotechnology industry could impact Vertex's ability to maintain its market position and revenue growth.
-
Investing in biotechnology companies like Vertex Pharmaceuticals carries inherent risks due to the complex nature of drug development and regulatory approvals.
#19 - Boston Scientific
NYSE:BSX - See Stock Forecast- Stock Price:
- $78.80 (+$0.32)
- Market Cap:
- $115.61 billion
- P/E Ratio:
- 66.2
- Consensus Rating:
- Moderate Buy (1 Strong Buy Ratings, 18 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $84.76 (7.6% Upside)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Boston Scientific Stock
Pros
-
Boston Scientific's stock price has been consistently increasing, reaching $78.26 on the latest trading day, indicating positive market sentiment.
-
The company has a strong market capitalization of $114.82 billion, reflecting its stability and potential for growth.
-
Boston Scientific reported earnings per share of $0.56 for the last quarter, surpassing analysts' estimates by $0.05, showcasing strong financial performance.
Cons
-
Despite positive financial performance, Boston Scientific's P/E ratio of 65.18 and PEG ratio of 2.67 may indicate that the stock is currently overvalued, posing a risk for potential investors.
-
The company's debt-to-equity ratio of 0.47 suggests a moderate level of debt, which could impact its financial flexibility and increase risk during economic downturns.
-
Insiders have sold a significant number of shares in the last ninety days, amounting to 0.50% of the total stock, which might signal lack of confidence from within the company.
#20 - Medtronic
NYSE:MDT - See Stock Forecast- Stock Price:
- $87.51 (+$2.13)
- Market Cap:
- $112.21 billion
- P/E Ratio:
- 31.8
- Dividend Yield:
- 3.35%
- Consensus Rating:
- Hold (0 Strong Buy Ratings, 3 Buy Ratings, 9 Hold Ratings, 1 Sell Ratings)
- Consensus Price Target:
- $91.50 (4.6% Upside)
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Medtronic Stock
Pros
-
Medtronic reported a strong EPS of $1.46 for the quarter, surpassing analysts' estimates by $0.01, indicating solid financial performance.
-
The company's revenue of $8.59 billion in the quarter exceeded the consensus estimate, demonstrating healthy growth.
-
Medtronic announced a quarterly dividend of $0.70 per share, providing investors with a steady income stream.
Cons
-
Some research firms have downgraded Medtronic's rating and lowered price targets, indicating potential concerns about future performance.
-
Medtronic's dividend payout ratio is currently high at 101.82%, which may raise questions about sustainability and future dividend growth.
-
Analysts predict a lower EPS of 5.44 for the current fiscal year compared to previous periods, suggesting potential challenges ahead.
#21 - HCA Healthcare
NYSE:HCA - See Stock Forecast- Stock Price:
- $376.62 (+$1.31)
- Market Cap:
- $98.64 billion
- P/E Ratio:
- 18.8
- Dividend Yield:
- 0.71%
- Consensus Rating:
- Moderate Buy (1 Strong Buy Ratings, 14 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $354.67 (-5.8% Downside)
HCA Healthcare, Inc., through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, it operates behavioral hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.
#22 - Bristol-Myers Squibb
NYSE:BMY - See Stock Forecast- Stock Price:
- $48.44 (-$0.54)
- Market Cap:
- $98.19 billion
- Dividend Yield:
- 4.89%
- Consensus Rating:
- Hold (0 Strong Buy Ratings, 2 Buy Ratings, 13 Hold Ratings, 1 Sell Ratings)
- Consensus Price Target:
- $54.86 (13.2% Upside)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Bristol-Myers Squibb Stock
Pros
-
Bristol-Myers Squibb has a strong portfolio of biopharmaceutical products for various diseases including hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience.
-
The company has been actively discovering, developing, and licensing new products, showing a commitment to innovation and growth.
-
Recent developments in the company's pipeline show promising results in clinical trials, indicating potential future revenue growth.
Cons
-
While the company has a strong product portfolio, it also faces competition from other pharmaceutical companies in the market, which could impact its market share and profitability.
-
Regulatory challenges and changes in healthcare policies could affect Bristol-Myers Squibb's operations and financial performance.
-
The biopharmaceutical industry is highly regulated and subject to risks such as clinical trial failures, patent expirations, and pricing pressures, which could impact the company's revenue and profitability.
#23 - The Cigna Group
NYSE:CI - See Stock Forecast- Stock Price:
- $342.20 (-$0.40)
- Market Cap:
- $97.21 billion
- P/E Ratio:
- 28.1
- Dividend Yield:
- 1.66%
- Consensus Rating:
- Buy (1 Strong Buy Ratings, 13 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $384.86 (12.5% Upside)
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. In addition, it offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of The Cigna Group Stock
Pros
-
The Cigna Group has received multiple positive ratings from analysts, including "strong-buy" and "overweight" ratings, indicating high confidence in the company's performance and potential growth.
-
Recent insider activity shows selling of company stock, which could be interpreted as a positive sign by investors, suggesting that insiders believe the stock price is at a favorable level.
-
The company's stock price has shown resilience, with a 52-week high of $365.71, indicating strong performance and potential for further growth.
Cons
-
Despite positive ratings and price targets, there is a risk of market volatility affecting the stock price of The Cigna Group, which could lead to potential losses for investors.
-
Insider selling activity, while sometimes viewed positively, could also signal concerns about the company's future performance or challenges ahead, prompting caution among investors.
-
The company's debt-to-equity ratio of 0.75 may raise concerns about its financial leverage and ability to manage debt obligations, posing a risk to investors in case of economic downturns.
#24 - Gilead Sciences
NASDAQ:GILD - See Stock Forecast- Stock Price:
- $75.13 (+$0.38)
- Market Cap:
- $93.60 billion
- P/E Ratio:
- 208.7
- Dividend Yield:
- 4.14%
- Consensus Rating:
- Hold (1 Strong Buy Ratings, 7 Buy Ratings, 12 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $81.94 (9.1% Upside)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Gilead Sciences Stock
Pros
-
Gilead Sciences reported a strong EPS of $2.01 for the quarter ending August 8th, surpassing the consensus estimate by $0.40. This indicates the company's profitability and potential for growth.
-
The company has a low debt-to-equity ratio of 1.31, which signifies a healthy financial structure and lower risk compared to companies with higher debt levels.
-
Analysts have set a consensus price target of $81.81 for Gilead Sciences, indicating potential upside in the stock price based on market expectations.
Cons
-
The stock's P/E ratio of 203.28 is relatively high, indicating that the stock may be overvalued compared to industry peers or historical averages, potentially limiting immediate upside potential.
-
Gilead Sciences' price-to-earnings-growth (PEG) ratio of 3.37 suggests that the stock may be overpriced relative to its earnings growth potential, which could lead to a correction in the stock price.
-
The company's revenue growth rate of 5.3% year-over-year may be considered modest, raising concerns about the company's ability to drive significant top-line growth in a competitive market environment.
#25 - GSK
NYSE:GSK - See Stock Forecast- Stock Price:
- $41.85 (+$0.25)
- Market Cap:
- $86.73 billion
- P/E Ratio:
- 15.2
- Dividend Yield:
- 3.64%
- Consensus Rating:
- Buy (3 Strong Buy Ratings, 2 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $50.00 (19.5% Upside)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of GSK Stock
Pros
-
GSK's current stock price is $40.01, showing stability and potential for growth.
-
GSK has a dividend yield of 3.82%, providing investors with a steady income stream.
-
Recent analyst reports have rated GSK as a "strong-buy" and "buy," indicating positive sentiment from Wall Street.
Cons
-
GSK's stock price has a 52-week high of $45.92, indicating potential volatility in the market.
-
While GSK has a dividend yield, the yield of 3.82% may be lower compared to other investment opportunities.
-
Some analysts have rated GSK as "neutral," suggesting mixed opinions on the stock's performance.
#26 - Zoetis
NYSE:ZTS - See Stock Forecast- Stock Price:
- $182.81 (-$0.79)
- Market Cap:
- $83.42 billion
- P/E Ratio:
- 35.2
- Dividend Yield:
- 0.94%
- Consensus Rating:
- Buy (1 Strong Buy Ratings, 8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $217.11 (18.8% Upside)
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Zoetis Stock
Pros
-
Zoetis Inc. reported a strong quarterly earnings performance, beating the consensus estimate by $0.07 with an EPS of $1.56. This indicates the company's financial health and potential for growth.
-
The company has a solid return on equity of 50.67%, showcasing efficient utilization of shareholder funds to generate profits.
-
Zoetis Inc. has a robust net margin of 26.29%, indicating its ability to convert revenue into profit effectively.
Cons
-
Zoetis Inc. stock has experienced a 0.8% decrease, indicating short-term volatility that may pose risks to investors.
-
The company's P/E ratio of 35.42 suggests the stock may be relatively expensive compared to its earnings, potentially limiting immediate returns for investors.
-
With a debt-to-equity ratio of 1.32, Zoetis Inc. has a significant level of debt that could impact its financial flexibility and increase risk for investors.
#27 - McKesson
NYSE:MCK - See Stock Forecast- Stock Price:
- $558.24 (+$9.72)
- Market Cap:
- $72.54 billion
- P/E Ratio:
- 24.9
- Dividend Yield:
- 0.45%
- Consensus Rating:
- Moderate Buy (0 Strong Buy Ratings, 13 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $620.29 (11.1% Upside)
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment offers distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of McKesson Stock
Pros
-
McKesson's stock price has been showing an upward trend, reaching $617.51 on the latest trading day, indicating positive market sentiment.
-
Analysts have given McKesson a "Moderate Buy" rating with an average price target of $599.33, suggesting potential for growth.
-
Recent insider trading activities show confidence in the company, with corporate insiders owning 0.11% of the stock and recent purchases by large investors.
Cons
-
McKesson's stock performance has shown volatility, with fluctuations in the stock price despite overall positive analyst ratings.
-
The company's beta of 0.45 indicates lower volatility compared to the market average, potentially limiting short-term gains for investors seeking higher risk-reward opportunities.
-
Recent insider selling activities, including significant sales by company executives, may raise concerns about future growth prospects or internal confidence in the company.
#28 - Aetna
NYSE:AET - See Stock Forecast- Stock Price:
- $212.70
- Market Cap:
- $69.64 billion
- P/E Ratio:
- 21.6
- Dividend Yield:
- 0.94%
- Consensus Rating:
- N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- N/A
Aetna Inc. operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment offers medical, pharmacy benefit management service, dental, behavioral health, and vision plans on an insured and employer-funded basis. It also provides point-of-service, preferred provider organization, health maintenance organization, and indemnity benefit plans, as well as health savings accounts and consumer-directed health plans. In addition, this segment offers Medicare and Medicaid products and services, as well as other medical products, such as medical management and data analytics services, medical stop loss insurance, workers' compensation administrative services, and products that provide access to its provider networks in select geographies. The Group Insurance segment offers life insurance products, including group term life insurance, voluntary spouse and dependent term life insurance, group universal life insurance, and accidental death and dismemberment insurance; disability insurance products; and long-term care insurance products, which provide the benefits to cover the cost of care in private home settings, adult day care, assisted living, or nursing facilities. The Large Case Pensions segment manages various retirement products comprising pension and annuity products primarily for tax-qualified pension plans. The company provides its products and services to employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Aetna Inc. was founded in 1853 and is based in Hartford, Connecticut.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Aetna Stock
Pros
-
Aetna Inc. has a strong presence in the health care benefits industry, offering a wide range of services including medical, pharmacy, dental, and vision plans.
-
The company's diversified segments, such as Health Care, Group Insurance, and Large Case Pensions, provide stability and multiple revenue streams.
-
Aetna Inc. has a long-standing history dating back to 1853, showcasing its experience and resilience in the market.
Cons
-
Regulatory challenges in the health insurance industry could impact Aetna Inc.'s operations and profitability.
-
Competition in the managed health care subindustry may pose challenges for Aetna Inc.'s market share and growth prospects.
-
Changes in government policies related to health care could affect Aetna Inc.'s business model and financial performance.
#29 - Becton, Dickinson and Company
NYSE:BDX - See Stock Forecast- Stock Price:
- $234.76 (+$0.02)
- Market Cap:
- $67.85 billion
- P/E Ratio:
- 51.7
- Dividend Yield:
- 1.62%
- Consensus Rating:
- Moderate Buy (0 Strong Buy Ratings, 7 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $279.50 (19.1% Upside)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Becton, Dickinson and Company Stock
Pros
-
Becton, Dickinson and Company develops, manufactures, and sells a wide range of medical supplies, devices, laboratory equipment, and diagnostic products for various healthcare needs.
-
BCAL Diagnostics Limited, a subsidiary of Becton, Dickinson and Company, is working on developing a non-invasive blood test for the detection of breast cancer, which could have significant implications in the field of cancer screening and prevention.
Cons
-
No specific cons were found in the recent data for Becton, Dickinson and Company.
#30 - Allergan
NYSE:AGN - See Stock Forecast- Stock Price:
- $193.02
- Market Cap:
- $63.50 billion
- Dividend Yield:
- 1.53%
- Consensus Rating:
- N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- N/A
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
#31 - Shire
NASDAQ:SHPG - See Stock Forecast- Stock Price:
- $179.20
- Market Cap:
- $54.71 billion
- P/E Ratio:
- 11.8
- Dividend Yield:
- 0.19%
- Consensus Rating:
- N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- N/A
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.
#32 - Express Scripts
NASDAQ:ESRX - See Stock Forecast- Stock Price:
- $92.33
- Market Cap:
- $52.06 billion
- P/E Ratio:
- 13.0
- Consensus Rating:
- N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- N/A
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Express Scripts Stock
Pros
-
Express Scripts Holding has recently announced strategic cost-cutting measures, which could lead to improved profitability and shareholder value.
-
The company's focus on expanding its specialty pharmacy services could drive revenue growth, as specialty medications are high-margin products.
-
Express Scripts Holding's strong presence in the pharmacy benefit management sector provides stability and a competitive edge in the healthcare services industry.
Cons
-
Regulatory changes in the healthcare industry could impact Express Scripts Holding's operations and profitability, leading to uncertainties for investors.
-
The increasing competition in the pharmacy benefit management sector may put pressure on Express Scripts Holding's market share and pricing power.
-
Concerns about potential disruptions in the supply chain of pharmaceuticals and medical supplies could affect the company's ability to deliver services efficiently.
#33 - Cencora
NYSE:COR - See Stock Forecast- Stock Price:
- $239.27 (+$0.86)
- Market Cap:
- $47.72 billion
- P/E Ratio:
- 26.2
- Dividend Yield:
- 0.86%
- Consensus Rating:
- Moderate Buy (0 Strong Buy Ratings, 6 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $258.63 (8.1% Upside)
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Cencora Stock
Pros
-
Cencora, Inc. reported strong quarterly earnings, beating consensus estimates by $0.16 per share, indicating a healthy financial performance.
-
The company has a solid return on equity of 266.60%, showcasing efficient utilization of shareholder funds to generate profits.
-
Cencora's dividend payout ratio (DPR) is currently at 22.32%, providing investors with a steady income stream through dividends.
Cons
-
Despite positive ratings and price targets from analysts, there have been recent downgrades in the stock's rating, which may indicate underlying concerns.
-
Cencora's net margin of 0.65% is relatively low, raising questions about the company's profitability and cost management.
-
The stock's 52-week low of $171.65 suggests potential volatility in the market, posing risks for investors seeking stable returns.
#34 - Takeda Pharmaceutical
NYSE:TAK - See Stock Forecast- Stock Price:
- $14.94 (+$0.18)
- Market Cap:
- $47.28 billion
- P/E Ratio:
- 27.2
- Dividend Yield:
- 3.24%
- Consensus Rating:
- N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $14.00 (-6.3% Downside)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
#35 - Alcon
NYSE:ALC - See Stock Forecast- Stock Price:
- $94.62 (-$1.88)
- Market Cap:
- $46.66 billion
- P/E Ratio:
- 44.8
- Dividend Yield:
- 0.29%
- Consensus Rating:
- Moderate Buy (0 Strong Buy Ratings, 12 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)
- Consensus Price Target:
- $97.28 (2.8% Upside)
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Alcon Stock
Pros
-
Alcon Inc. has shown a positive Fifty-Two Week Performance, indicating potential growth.
-
The recent decrease in Shares Shorted from the previous month could lead to a positive impact on the stock price.
-
Alcon Inc. has a relatively low Short Percentage of Float, which may indicate lower market pessimism.
Cons
-
The Institutional Ownership Percentage is currently at 0.603, which may indicate limited interest from institutional investors.
-
The recent increase in Shares Shorted from the previous month could lead to increased selling pressure on the stock.
-
Alcon Inc. has a relatively high Short Percentage of Float, which may indicate higher market pessimism.
#36 - Haleon
NYSE:HLN - See Stock Forecast- Stock Price:
- $9.87 (+$0.02)
- Market Cap:
- $45.07 billion
- P/E Ratio:
- 32.9
- Dividend Yield:
- 2.15%
- Consensus Rating:
- Moderate Buy (0 Strong Buy Ratings, 4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- N/A
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Haleon Stock
Pros
-
Haleon plc has shown consistent growth in its stock price, currently trading at $9.81, with a market capitalization of $44.79 billion.
-
The company has a strong financial position with a current ratio of 1.04 and a quick ratio of 0.73, indicating good liquidity.
-
Analysts have set a "Moderate Buy" rating on Haleon plc, suggesting positive sentiment and growth potential in the stock.
Cons
-
Despite positive analyst ratings, there is a level of uncertainty in the market that could impact the stock price of Haleon plc.
-
The company operates in a competitive industry, facing challenges from other healthcare product manufacturers that could affect market share.
-
There is a debt-to-equity ratio of 0.53, indicating a moderate level of leverage that could pose risks in a changing economic environment.
#37 - IQVIA
NYSE:IQV - See Stock Forecast- Stock Price:
- $247.00 (+$0.06)
- Market Cap:
- $44.99 billion
- P/E Ratio:
- 33.7
- Consensus Rating:
- Moderate Buy (1 Strong Buy Ratings, 12 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $265.67 (7.6% Upside)
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of IQVIA Stock
Pros
-
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry globally.
-
The company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, providing diversified revenue streams.
-
IQVIA has a strong track record of innovation and technological advancements in the healthcare sector, positioning itself as a leader in the industry.
Cons
-
While IQVIA has a strong presence in the healthcare industry, it also faces intense competition from other major players, which could impact its market share and profitability.
-
The company's reliance on regulatory approvals and changes in healthcare policies could introduce uncertainties and risks to its operations and financial performance.
-
IQVIA's business model is subject to fluctuations in demand for its services, which may be influenced by economic conditions and industry trends.
#38 - Humana
NYSE:HUM - See Stock Forecast- Stock Price:
- $358.55 (+$1.57)
- Market Cap:
- $43.21 billion
- P/E Ratio:
- 22.3
- Dividend Yield:
- 0.99%
- Consensus Rating:
- Hold (0 Strong Buy Ratings, 9 Buy Ratings, 12 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $396.35 (10.5% Upside)
Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of pharmacy benefit manager business. Further, it operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. The company sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
#39 - Seagen
NASDAQ:SGEN - See Stock Forecast- Stock Price:
- $228.74
- Market Cap:
- $42.93 billion
- Consensus Rating:
- Hold (0 Strong Buy Ratings, 0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $229.00 (0.1% Upside)
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Seagen Stock
Pros
-
Seagen Inc. has shown a consistent month-to-month increase in shares shorted, indicating growing interest from investors.
-
The institutional ownership percentage of Seagen Inc. is high at 91.8%, suggesting confidence from large financial institutions.
-
Seagen Inc.'s fifty-two week performance has been positive at 67.25%, outperforming the market average.
Cons
-
Seagen Inc.'s float size is reported as 0, which may limit liquidity and impact trading volume.
-
Despite the positive performance, Seagen Inc. has a relatively low average daily volume of 1,360,000 shares, which could affect ease of buying or selling.
-
The outstanding shares of Seagen Inc. stand at 181,480,000, potentially diluting the value of existing shares.
#40 - Edwards Lifesciences
NYSE:EW - See Stock Forecast- Stock Price:
- $70.09 (+$0.71)
- Market Cap:
- $42.24 billion
- P/E Ratio:
- 30.2
- Consensus Rating:
- Moderate Buy (1 Strong Buy Ratings, 11 Buy Ratings, 13 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $82.10 (17.1% Upside)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
#41 - Centene
NYSE:CNC - See Stock Forecast- Stock Price:
- $78.40 (+$0.24)
- Market Cap:
- $41.84 billion
- P/E Ratio:
- 15.6
- Consensus Rating:
- Hold (0 Strong Buy Ratings, 6 Buy Ratings, 9 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $84.36 (7.6% Upside)
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support. This segment also provides healthcare products. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual, small, and large group commercials. It also operates clinical healthcare and pharmacies, as well as offers dental and speech therapy services. In addition, the company engages in the government contracts business under the TRICARE program and other healthcare related government contracts. It provides services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in Saint Louis, Missouri.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Centene Stock
Pros
-
Centene's stock price has been showing a consistent upward trend, indicating potential for capital appreciation.
-
The company has a strong market capitalization of $41.68 billion, reflecting stability and investor confidence.
-
Centene's recent quarterly earnings report showed a revenue increase of 5.9%, demonstrating growth and financial health.
Cons
-
Centene's debt-to-equity ratio of 0.64 may indicate higher financial leverage, which could pose risks during economic downturns.
-
The company's PE ratio of 15.55 is relatively higher compared to industry peers, potentially signaling overvaluation.
-
There have been recent insider sales of Centene stock by company directors, which could raise concerns about future performance.
#42 - IDEXX Laboratories
NASDAQ:IDXX - See Stock Forecast- Stock Price:
- $494.99 (+$0.98)
- Market Cap:
- $40.88 billion
- P/E Ratio:
- 47.9
- Consensus Rating:
- Moderate Buy (0 Strong Buy Ratings, 7 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $582.25 (17.6% Upside)
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
#43 - Alexion Pharmaceuticals
NASDAQ:ALXN - See Stock Forecast- Stock Price:
- $182.50
- Market Cap:
- $40.34 billion
- P/E Ratio:
- 59.6
- Consensus Rating:
- N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- N/A
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
#44 - GE HealthCare Technologies
NASDAQ:GEHC - See Stock Forecast- Stock Price:
- $84.48 (+$0.54)
- Market Cap:
- $38.56 billion
- P/E Ratio:
- 24.7
- Dividend Yield:
- 0.14%
- Consensus Rating:
- Moderate Buy (1 Strong Buy Ratings, 6 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $95.00 (12.5% Upside)
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of GE HealthCare Technologies Stock
Pros
-
GEHC stock price trading at $80.82 on August 11, 2024, showing stability in the market.
-
GE HealthCare Technologies Inc. has a market capitalization of $36.89 billion, indicating a strong presence in the industry.
-
Recent insider selling activities suggest confidence in the company's future growth prospects.
Cons
-
Debt-to-equity ratio of 1.11, which may indicate higher financial leverage and associated risks.
-
Decline in stock price from the one-year high of $94.50 to $80.82, signaling potential volatility in the market.
-
Lower than expected quick ratio of 0.83, suggesting potential liquidity challenges for the company.
#45 - Alnylam Pharmaceuticals
NASDAQ:ALNY - See Stock Forecast- Stock Price:
- $279.17 (-$1.59)
- Market Cap:
- $35.31 billion
- Consensus Rating:
- Moderate Buy (0 Strong Buy Ratings, 17 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $277.14 (-0.7% Downside)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
#46 - ResMed
NYSE:RMD - See Stock Forecast- Stock Price:
- $224.16 (+$1.01)
- Market Cap:
- $33.46 billion
- P/E Ratio:
- 34.4
- Dividend Yield:
- 0.93%
- Consensus Rating:
- Moderate Buy (0 Strong Buy Ratings, 6 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $204.70 (-8.7% Downside)
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of ResMed Stock
Pros
-
ResMed Inc. has recently launched a new innovative product that is gaining traction in the market.
-
The company's stock price has been steadily increasing over the past year, indicating positive investor sentiment.
-
ResMed Inc. has a strong financial position with healthy cash reserves and low debt levels.
Cons
-
There is increasing competition in the healthcare industry, which could impact ResMed Inc.'s market share and profitability.
-
The company's stock price is currently at a high valuation, which may limit potential upside for investors.
-
ResMed Inc. is facing regulatory challenges in certain markets, which could affect its growth prospects.
#47 - Moderna
NASDAQ:MRNA - See Stock Forecast- Stock Price:
- $86.65 (-$0.29)
- Market Cap:
- $33.21 billion
- Consensus Rating:
- Hold (0 Strong Buy Ratings, 7 Buy Ratings, 8 Hold Ratings, 1 Sell Ratings)
- Consensus Price Target:
- $124.07 (43.2% Upside)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Moderna Stock
Pros
-
Moderna's stock price has shown resilience, trading at $86.62 on the NASDAQ as of today, indicating potential value for investors.
-
Moderna has a strong pipeline of messenger RNA therapeutics and vaccines targeting various diseases, providing diversification and growth opportunities.
-
Recent analyst reports have maintained positive ratings on Moderna, with price targets indicating potential upside for investors.
Cons
-
Moderna's stock has experienced volatility in the past, which may pose risks for investors seeking stable returns.
-
The biotechnology sector is highly competitive and subject to regulatory challenges, impacting Moderna's growth potential.
-
Insider selling activity in the company raises concerns about management sentiment and future performance expectations.
#48 - argenx
NASDAQ:ARGX - See Stock Forecast- Stock Price:
- $525.50 (+$1.51)
- Market Cap:
- $31.23 billion
- Consensus Rating:
- Moderate Buy (1 Strong Buy Ratings, 18 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $540.37 (2.8% Upside)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of argenx Stock
Pros
-
argenx SE has a strong pipeline of innovative therapies targeting various autoimmune diseases, providing potential for significant revenue growth.
-
The company's lead product candidate, efgartigimod, has shown promising results in multiple indications, indicating a potential for widespread adoption and commercial success.
-
Analysts have set a consensus price target of $533.47 for ARGX, suggesting potential for substantial stock price appreciation from its current levels.
Cons
-
argenx SE operates in a highly competitive biotechnology sector, facing challenges from established players and potential disruptions from new entrants.
-
The stock price of argenx SE has a high price-to-earnings ratio of -83.27, which may indicate overvaluation and pose risks for investors in terms of potential corrections.
-
While analysts have issued positive ratings for ARGX, there is always a degree of uncertainty in biopharmaceutical investments due to regulatory approvals, clinical trial outcomes, and market dynamics.
#49 - Biogen
NASDAQ:BIIB - See Stock Forecast- Stock Price:
- $206.18 (+$0.69)
- Market Cap:
- $30.02 billion
- P/E Ratio:
- 25.7
- Consensus Rating:
- Moderate Buy (0 Strong Buy Ratings, 17 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $276.35 (34.0% Upside)
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of Biogen Stock
Pros
-
Biogen Inc. reported a strong quarterly earnings performance, beating analysts' consensus estimates by $1.28 per share, indicating positive financial health and potential for growth.
-
The company has a solid return on equity of 15.71%, showcasing efficient utilization of shareholder funds to generate profits.
-
Biogen Inc. has a diverse portfolio of biotechnology products, reducing dependency on a single product and spreading risk across multiple revenue streams.
Cons
-
Biogen Inc.'s stock has experienced recent downward trends, trading down 2.4% and hitting $205.66, potentially signaling short-term volatility or market uncertainties.
-
The company's PEG ratio of 2.09 may indicate that the stock is currently overvalued relative to its earnings growth potential, posing a risk for investors seeking value.
-
Biogen Inc. operates in the biotechnology sector, which is subject to regulatory challenges, clinical trial outcomes, and patent expirations, leading to inherent industry risks.
#50 - DexCom
NASDAQ:DXCM - See Stock Forecast- Stock Price:
- $73.20 (+$0.35)
- Market Cap:
- $29.11 billion
- P/E Ratio:
- 47.2
- Consensus Rating:
- Moderate Buy (1 Strong Buy Ratings, 11 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- $111.63 (52.5% Upside)
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Pros and Cons of DexCom Stock
Pros
-
DexCom reported earnings per share of $0.43 for the last quarter, surpassing analysts' estimates by $0.04, indicating strong financial performance.
-
Institutional investors, such as Vanguard Group Inc. and Capital World Investors, have significantly increased their holdings in DexCom, showing confidence in the company's future growth potential.
-
The company's revenue for the quarter was $1 billion, slightly below expectations but still demonstrating a solid financial position.
Cons
-
Insiders sold 4,112 shares of company stock in the last quarter, potentially signaling lack of confidence in short-term stock performance.
-
The stock's PE ratio of 46.65 and P/E/G ratio of 2.18 indicate that the stock may be overvalued compared to its growth prospects, posing a risk for investors.
-
DexCom's stock price has experienced fluctuations, with a 52-week high of $142.00 and a 52-week low of $62.34, suggesting volatility in the market.